321 related articles for article (PubMed ID: 19468270)
41. Long-term survival after significant treatment reduction in a patient with CBF-AML.
Driessen EM; van der Velden VH; Catsman-Berrevoets CE; van den Heuvel-Eibrink MM; Beishuizen A
Pediatr Blood Cancer; 2011 Feb; 56(2):325-6. PubMed ID: 21157900
[No Abstract] [Full Text] [Related]
42. KIT and FLT3 receptor tyrosine kinase mutations in acute myeloid leukemia with favorable cytogenetics: two novel mutations and selective occurrence in leukemia subtypes and age groups.
Sritana N; Auewarakul CU
Exp Mol Pathol; 2008 Dec; 85(3):227-31. PubMed ID: 18977345
[TBL] [Abstract][Full Text] [Related]
43. [Acute myeloid leukemia (AML)].
Büchner T
Praxis (Bern 1994); 1999 Mar; 88(10):421-30. PubMed ID: 10199214
[TBL] [Abstract][Full Text] [Related]
44. Low dose interleukin-2 following intensification therapy with high dose cytarabine for acute myelogenous leukemia in first complete remission.
Stone RM; DeAngelo DJ; Janosova A; Galinsky I; Canning C; Ritz J; Soiffer RJ
Am J Hematol; 2008 Oct; 83(10):771-7. PubMed ID: 18756547
[TBL] [Abstract][Full Text] [Related]
45. Current treatment of acute myeloid leukemia.
Roboz GJ
Curr Opin Oncol; 2012 Nov; 24(6):711-9. PubMed ID: 23014187
[TBL] [Abstract][Full Text] [Related]
46. Expression of the neural cell adhesion molecule CD56 is not associated with P-glycoprotein overexpression in core-binding factor acute myeloid leukemia.
Suvannasankha A; Minderman H; O'Loughlin KL; Sait SN; Stewart CC; Greco WR; Baer MR
Leuk Res; 2004 May; 28(5):449-55. PubMed ID: 15068897
[TBL] [Abstract][Full Text] [Related]
47. [Genetic abnormalities in core binding factor acute myeloid leukemia].
Ishikawa Y
Rinsho Ketsueki; 2017; 58(8):991-998. PubMed ID: 28883285
[TBL] [Abstract][Full Text] [Related]
48. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype.
Breems DA; Van Putten WL; De Greef GE; Van Zelderen-Bhola SL; Gerssen-Schoorl KB; Mellink CH; Nieuwint A; Jotterand M; Hagemeijer A; Beverloo HB; Löwenberg B
J Clin Oncol; 2008 Oct; 26(29):4791-7. PubMed ID: 18695255
[TBL] [Abstract][Full Text] [Related]
49. Gene-expression profiling identifies distinct subclasses of core binding factor acute myeloid leukemia.
Bullinger L; Rücker FG; Kurz S; Du J; Scholl C; Sander S; Corbacioglu A; Lottaz C; Krauter J; Fröhling S; Ganser A; Schlenk RF; Döhner K; Pollack JR; Döhner H
Blood; 2007 Aug; 110(4):1291-300. PubMed ID: 17485551
[TBL] [Abstract][Full Text] [Related]
50. Has gene expression profiling improved diagnosis, classification, and outcome prediction in AML?
Willman CL
Best Pract Res Clin Haematol; 2008 Mar; 21(1):21-8. PubMed ID: 18342809
[TBL] [Abstract][Full Text] [Related]
51. Gene expression profiling in acute myeloid leukemia.
Bullinger L; Valk PJ
J Clin Oncol; 2005 Sep; 23(26):6296-305. PubMed ID: 16155012
[TBL] [Abstract][Full Text] [Related]
52. Additional chromosomal abnormalities in core-binding factor acute myeloid leukemia.
Hsiao HH; Liu YC; Wang HC; Tsai YF; Wu CH; Cho SF; Hsu JF; Huang CT; Hsiao SY; Lee CP; Chang CS; Lin SF; Liu TC
Genet Mol Res; 2015 Dec; 14(4):17028-33. PubMed ID: 26681050
[TBL] [Abstract][Full Text] [Related]
53. Therapy of core binding factor acute myeloid leukemia: incremental improvements toward better long-term results.
Bhatt VR; Kantarjian H; Cortes JE; Ravandi F; Borthakur G
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):153-8. PubMed ID: 23266036
[TBL] [Abstract][Full Text] [Related]
54. Prognostic Significance of KIT Mutations in Core-Binding Factor Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis.
Chen W; Xie H; Wang H; Chen L; Sun Y; Chen Z; Li Q
PLoS One; 2016; 11(1):e0146614. PubMed ID: 26771376
[TBL] [Abstract][Full Text] [Related]
55. Core-binding factor abnormalities involving chromosome 16 in acute myeloid leukaemia: prognostic and therapeutic implications.
Panigrahi C; Tikare N; Das PK; Padhi S
BMJ Case Rep; 2023 Aug; 16(8):. PubMed ID: 37591621
[TBL] [Abstract][Full Text] [Related]
56. Prognostic of Core Binding Factor (CBF) Acute Myeloid Leukemia With Complex Karyotype.
Marcault C; Boissel N; Haferlach C; Loschi M; Raynaud S; Cluzeau T
Clin Lymphoma Myeloma Leuk; 2022 Mar; 22(3):e199-e205. PubMed ID: 34674982
[TBL] [Abstract][Full Text] [Related]
57. Is it time to change conventional consolidation chemotherapy for acute myeloid leukemia in CR1?
Wolach O; Stone RM
Curr Opin Hematol; 2015 Mar; 22(2):123-31. PubMed ID: 25594168
[TBL] [Abstract][Full Text] [Related]
58. Impact of new prognostic markers in treatment decisions in acute myeloid leukemia.
Schlenk RF; Döhner K
Curr Opin Hematol; 2009 Mar; 16(2):98-104. PubMed ID: 19468271
[TBL] [Abstract][Full Text] [Related]
59. Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia.
Senapati J; Shoukier M; Garcia-Manero G; Wang X; Patel K; Kadia T; Ravandi F; Pemmaraju N; Ohanian M; Daver N; DiNardo C; Alvarado Y; Aldrich J; Borthakur G
Am J Hematol; 2022 May; 97(5):574-582. PubMed ID: 35150150
[TBL] [Abstract][Full Text] [Related]
60. Emerging treatment strategies for acute myeloid leukemia (AML) in the elderly.
Kuendgen A; Germing U
Cancer Treat Rev; 2009 Apr; 35(2):97-120. PubMed ID: 18951721
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
